381 related articles for article (PubMed ID: 21880806)
1. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.
Nikiforov YE; Ohori NP; Hodak SP; Carty SE; LeBeau SO; Ferris RL; Yip L; Seethala RR; Tublin ME; Stang MT; Coyne C; Johnson JT; Stewart AF; Nikiforova MN
J Clin Endocrinol Metab; 2011 Nov; 96(11):3390-7. PubMed ID: 21880806
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
Thyroid; 2015 Nov; 25(11):1217-23. PubMed ID: 26356635
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy.
Moses W; Weng J; Sansano I; Peng M; Khanafshar E; Ljung BM; Duh QY; Clark OH; Kebebew E
World J Surg; 2010 Nov; 34(11):2589-94. PubMed ID: 20703476
[TBL] [Abstract][Full Text] [Related]
4. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.
Nikiforov YE; Steward DL; Robinson-Smith TM; Haugen BR; Klopper JP; Zhu Z; Fagin JA; Falciglia M; Weber K; Nikiforova MN
J Clin Endocrinol Metab; 2009 Jun; 94(6):2092-8. PubMed ID: 19318445
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity.
Krane JF; Cibas ES; Alexander EK; Paschke R; Eszlinger M
Cancer Cytopathol; 2015 Jun; 123(6):356-61. PubMed ID: 25926393
[TBL] [Abstract][Full Text] [Related]
6. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
[TBL] [Abstract][Full Text] [Related]
7. Highly Sensitive and Specific Molecular Test for Mutations in the Diagnosis of Thyroid Nodules: A Prospective Study of
Cho YY; Park SY; Shin JH; Oh YL; Choe JH; Kim JH; Kim JS; Yim HS; Kim YL; Ki CS; Kim TH; Chung JH; Kim SW
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781560
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
9. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
Macerola E; Rago T; Proietti A; Basolo F; Vitti P
J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
[TBL] [Abstract][Full Text] [Related]
10. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
11. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
Johnson SJ; Hardy SA; Roberts C; Bourn D; Mallick U; Perros P
Cytopathology; 2014 Jun; 25(3):146-54. PubMed ID: 24417615
[TBL] [Abstract][Full Text] [Related]
12. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
13. Impact of ultrasonographic features, cytomorphology and mutational testing on malignant and indeterminate thyroid nodules on diagnostic accuracy of fine needle cytology samples: A prospective analysis of 141 patients.
Fulciniti F; Cipolletta Campanile A; Malzone MG; Chiofalo MG; Capiluongo A; Monaco M; Di Maio N; Sandomenico F; Botti G; Chiappetta G; Vuttariello E; Pezzullo L
Clin Endocrinol (Oxf); 2019 Dec; 91(6):851-859. PubMed ID: 31483883
[TBL] [Abstract][Full Text] [Related]
14. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
[TBL] [Abstract][Full Text] [Related]
15. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.
Bellevicine C; Migliatico I; Sgariglia R; Nacchio M; Vigliar E; Pisapia P; Iaccarino A; Bruzzese D; Fonderico F; Salvatore D; Biondi B; Masone S; Novizio V; Scavuzzo F; Serino D; De Palma M; Chiofalo MG; Botti G; Pezzullo L; Nuzzo V; Spiezia S; De Chiara G; Iorio S; Conzo G; Docimo G; Faggiano A; Bongiovanni M; Malapelle U; Colao A; Triassi M; Troncone G;
Cancer Cytopathol; 2020 Feb; 128(2):107-118. PubMed ID: 31821746
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany.
Eszlinger M; Böhme K; Ullmann M; Görke F; Siebolts U; Neumann A; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Ruschenburg I; Paschke R
Thyroid; 2017 Mar; 27(3):402-411. PubMed ID: 28071986
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
Hall EA; Hartzband P; VanderLaan PA; Nishino M
Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
[TBL] [Abstract][Full Text] [Related]
19. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
20. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules.
Eszlinger M; Krogdahl A; Münz S; Rehfeld C; Precht Jensen EM; Ferraz C; Bösenberg E; Drieschner N; Scholz M; Hegedüs L; Paschke R
Thyroid; 2014 Feb; 24(2):305-13. PubMed ID: 23837487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
